Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.81 |
| ▸ | MAPT | P10636 | 1/20 | 0.81 |
| ▸ | MEN1 | O00255 | 5/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.76 |
| ▸ | PKM | P14618 | 1/20 | 0.76 |
| ▸ | RECQL | P46063 | 1/20 | 0.71 |
| ▸ | POLB | P06746 | 3/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3432866 | 0.89 | LMNA (1.00) | LMNAMAPTMEN1KMT2APKM | |
| Ammonia Solution, Strong SCHEMBL5312050 | 0.86 | MAPT (0.77) | LMNAMAPTMEN1KMT2APKM | |
| SCHEMBL28481747 | 0.85 | LMNA (0.81) | LMNAMAPTMEN1KMT2APKM | |
| SCHEMBL29411883 | 0.85 | LMNA (0.81) | LMNAMAPTMEN1KMT2APKM | |
| SCHEMBL9597872 | 0.83 | MAPT (0.64) | LMNAMAPTMEN1KMT2APKM | |
| SCHEMBL9570295 | 0.83 | MAPT (0.64) | LMNAMAPTMEN1KMT2APKM | |
| SCHEMBL7514961 | 0.83 | MAPT (0.64) | LMNAMAPTMEN1KMT2APKM | |
| SCHEMBL10980298 | 0.82 | MAPK1 (0.71) | LMNAMAPTMEN1KMT2APKM | |
| SCHEMBL15063595 | 0.81 | MEN1 (0.69) | LMNAMAPTMEN1KMT2APKM | |
| SCHEMBL3750821 | 0.80 | POLB (0.80) | LMNAMAPTMEN1KMT2APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200399219-A1 | DUAL ACTING FKBP12 AND FKBP52 INHIBITORS | PLEX PHARMACEUTICALS, INC. | 2020-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399219-A1 | DUAL ACTING FKBP12 AND FKBP52 INHIBITORS | FKBP2, FKBP1B, FKBP1A | LMNA 4512/4885MAPT 204/4885MEN1 4813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.